New drug safety trial offers hope for cGVHD patients in india

NCT ID NCT07135973

Not yet recruiting Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests the safety of a drug called belumosudil in 26 Indian patients aged 12 and older who have chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants take the drug for up to 24 weeks, and doctors monitor for side effects and how well the disease responds. The goal is to see if belumosudil is safe enough for broader use in this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
belumosudil (a tablet taken by mouth)
What this could lead to
If it works, this could confirm that belumosudil is a safe option for managing chronic graft-versus-host disease in Indian patients.
What could go wrong
This is a small, single-arm safety study with only 26 participants, so results may not apply broadly. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.